HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.

Abstract
A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the radiolabeled anti-CD20 antibody. We instead combined radioimmunotherapy with immunotherapy targeting different B-cell antigens. We evaluated the anti-CD22 (90)Y-epratuzumab tetraxetan with the anti-CD20 veltuzumab in patients with aggressive lymphoma in whom at least one prior standard treatment had failed, but who had not undergone stem cell transplantation. Eighteen patients (median age 73 years, median of 3 prior treatments) received 200 mg/m(2) veltuzumab once-weekly for 4 weeks, with (90)Y-epratuzumab tetraxetan at planned doses in weeks 3 and 4, and (111)In-epratuzumab tetraxetan in week 2 for imaging and dosimetry. Veltuzumab effectively lowered levels of B cells in the blood prior to the radioimmunotherapy doses. No significant immunogenicity or change in pharmacokinetics of either agent occurred in combination. (111)In imaging showed tumor targeting with acceptable radiation dosimetry to normal organs. For (90)Y-epratuzumab tetraxetan, transient myelosuppression was dose-limiting with 6 mCi/m(2) (222 MBq/m(2)) × 2 being the maximal tolerated dose. Of 17 assessable patients, nine (53%) had objective responses according to the 2007 revised treatment response criteria, including three (18%) complete responses (2 relapsing after 11 and 13 months, 1 continuing to be clinically disease-free at 19 months), and six (35%) partial responses (1 relapsing after 14 months, 5 at 3 - 7 months). Responses occurred in patients with different lymphoma histologies, treated at different (90)Y dose levels, and with a predicted risk of poor outcome, most importantly including five of the six patients treated with the maximal tolerated dose (2 of whom achieved durable complete responses). In conclusion, the combination of (90)Y-epratuzumab tetraxetan and veltuzumab was well-tolerated with encouraging therapeutic activity in this difficult-to-treat population.
AuthorsThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, Ebenezer A Kio, Robert M Sharkey, William A Wegener, David M Goldenberg
JournalHaematologica (Haematologica) Vol. 99 Issue 11 Pg. 1738-45 (Nov 2014) ISSN: 1592-8721 [Electronic] Italy
PMID25150258 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
CopyrightCopyright© Ferrata Storti Foundation.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Indium Radioisotopes
  • Yttrium Radioisotopes
  • epratuzumab
  • veltuzumab
Topics
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Bone Marrow (pathology)
  • Disease Progression
  • Female
  • Humans
  • Indium Radioisotopes
  • Lymphoma, Non-Hodgkin (diagnosis, drug therapy, radiotherapy)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Radioimmunotherapy
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Yttrium Radioisotopes (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: